Saccharomyces cerevisiae-Derived Mannan Does Not Alter Immune Responses to Aspergillus Allergens

Abstract EN

Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure.

While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial.

Herein, we hypothesized that mannan from Saccharomyces cerevisiae would dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses.

Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness.

Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice.

Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability.

Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.